Analyst Price Target is C$27.63
▲ +216.44% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for HLS Therapeutics in the last 3 months. The average price target is C$27.63, with a high forecast of C$36.00 and a low forecast of C$22.00. The average price target represents a 216.44% upside from the last price of C$8.73.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in HLS Therapeutics. This Buy consensus rating has held steady for over two years.
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.